论文部分内容阅读
目的观察灯盏花注射液联合胰激肽原酶对早期糖尿病肾病的临床疗效。方法将60例患者随机分为2组,治疗组30例,给予灯盏花注射液30 ml加入0.9%氯化钠注射液250 ml静脉滴注,1次/d,胰激肽原酶片120 U,口服,3次/d,对照组30例,单独应用胰激肽原酶120 U,口服,3次/d,疗程2周,观察2组疗效。结果治疗后对照组和治疗组24 h尿微量白蛋白(UAER)均较治疗前明显减少,但联合治疗组显著优于对照组(P<0.05)。结论灯盏花注射液联合胰激肽原酶治疗早期糖尿病肾病疗效确切,安全性好。
Objective To observe the clinical efficacy of breviscapine injection combined with pancreatic kallikrein on early diabetic nephropathy. Methods Sixty patients were randomly divided into two groups. The treatment group consisted of 30 cases. Erigeron injection 30 ml and 0.9% sodium chloride injection 250 ml intravenous drip once per day, pancreatic kallikrein 120 U , Orally, 3 times / d, the control group of 30 cases, the application of pancreatic kallikrein 120 U, orally, 3 times / d, treatment for 2 weeks, the two groups were observed. Results After treatment, 24-hour urine microalbuminuria (UAER) in the control group and treatment group were significantly decreased compared with those before treatment, but the combination therapy group was significantly better than the control group (P <0.05). Conclusion Erigeron injection combined with pancreatic kallikrein treatment of early diabetic nephropathy, the exact effect of good safety.